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ABSTRACT
Background: The Risedronate and Alendronate (REAL) cohort study pro-
vides unique comparative effectiveness data for real world bisphosphonate
treatment of osteoporosis.
Objective: The objective of this analysis was to assess the cost-
effectiveness of risedronate compared to generic alendronate in Germany
applying the REAL effectiveness data.
Materials and Methods: A validated Markov model of osteoporosis was
populatedwith REAL effectiveness data andGerman epidemiological, cost,
and utility data. To estimate the impact of therapy on hip fractures, costs,
and quality adjusted life years (QALYs), the analysis included women65
years, treatedwith risedronate or alendronate and followed for 4 additional
years. Country-speciﬁc data included population mortality, fracture costs,
and annual drug costs, using a German social insurance perspective. Costs
and outcomes were discounted at 3%. A differential hip fracture relative
risk reduction of 43% was applied to risedronate vs. alendronate.
Results: The model predicted that treatment with risedronate would result
in fewer hip fractures and more QALYs at a reduced cost (savings of €278
per treated woman) compared to treatment with generic alendronate.
Sensitivity analysis assuming 2 years of treatment and equivalence of effect
after 1 year show cost savings as well (€106 per treated woman).
Discussion: Whereas previous economic evaluations involving bisphos-
phonates have mainly relied on efﬁcacy data from noncomparative clinical
trials, this study’s strength is in the use of comparative effectiveness data
from one data source. The magnitude of the cost savings observed were
sensitive to alternative assumptions regarding treatment duration, therapy
discontinuation and cost of generic alendronate.
Conclusions: Based on “real world” data the analysis supports the ﬁrst line
use of risedronate for the treatment of osteoporotic women in Germany.
Keywords: bisphosphonate, cost-effectiveness, cost-utility, hip fracture,
Markov chains model, osteoporosis.
Introduction
In Germany, osteoporosis affects approximately 7.8 million
people or 26% of the population 50 years of age or older [1]. The
total direct costs attributable to osteoporosis in the year 2003
were estimated at €5.4 billion, accounting for 3.5% of all health-
care expenditures by the social health insurance fund [1]. Inpatient
costs relating to fracture treatment accounted for more than half
(56%) of the total direct costs [1]. The prevalence and economic
burden of osteoporosis in Germany are expected to increase
signiﬁcantly over the next decade, due to the aging of the popu-
lation. Despite these estimates, data suggest a low awareness of
osteoporosis among physicians and the general population [2].
Bisphosphonates have been well established through random-
ized controlled trials (RCTs) as an efﬁcacious treatment for post-
menopausal women at high risk of fracture [3–9]. In Germany,
risedronate and alendronate are the most commonly used bis-
phosphonates accounting for more than 90% of the bisphospho-
nate market share. In a recent systematic review of the cost-
effectiveness of bisphosphonates, Fleurence et al. [10] identiﬁed
16 studies conducted in women with low bone mineral density
(BMD) [11–25]. Two studies included a comparison of risedr-
onate and alendronate [15,16]; both found risedronate to be
cost-effective relative to alendronate in patients aged 60 to
69 years of age with or without previous vertebral fracture.
Nevertheless, these studies were limited in that they combined
efﬁcacy data from independent sources in absence of head-to-
head clinical efﬁcacy data.
Although there remains no direct comparison of risedronate
and alendronate in RCTs, new comparative data now exist from
a medical claims database study. The RisedronatE and ALendr-
onate (REAL) study found that patients treated with risedronate
had an 18% (95% conﬁdence interval [CI]: 0.02–0.32) lower
incidence of nonvertebral fractures and a 43% (95% CI: 0.13–
0.63) lower incidence of hip fractures at 12 months, compared to
alendronate [26]. Beyond conventional RCTs, data from medical
claims databases can provide additional evidence of treatment
effectiveness in a broad population of patients who are pre-
scribed the drug according to actual clinical practice and provide
a unique opportunity to conduct comparative cost-effectiveness
analyses based on effectiveness data. Recent policy initiatives
reinforce that decision-makers are increasingly recognizing the
importance of incorporating real-world evidence into health care
and reimbursement decision-making [27].
Recently, Grima et al. [28] completed a cost-effectiveness
analysis using the REAL study in Canada and found brand
risedronate to be cost-effective relative to brand or generic alen-
dronate. This study provides a good starting point for assessing
the cost-effectiveness of bisphosphonate therapies utilizing real-
world data; however, the applicability of the conclusions may be
limited for other countries due to the use of Canadian epidemi-
ology and cost data. Typically, the generalizability of health
economic evaluations is cautioned due to factors such as health-
care resources and relative prices that vary from region to region
that might alter the cost-effectiveness result [29,30].
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Given the predicted increases in the burden of osteoporosis in
Germany, as well as the reported low awareness of this disease, it
is essential to evaluate the health economics of the most effective
therapies with the best available evidence. Therefore, utilizing the
unique effectiveness data available from the REAL study, as well
as German-speciﬁc epidemiology and cost data, the objective of
this study was to examine the cost-effectiveness of risedronate
compared to generic alendronate in the treatment of postmeno-
pausal women with osteoporosis in Germany.
Methods
A published Markov state-transition model [31] was adapted to
Germany to compare brand risedronate with generic alendronate
in the treatment of postmenopausal women 65 years of age or
older with osteoporosis (BMD T-score 2.5). Generic alendr-
onate was selected as the comparator because of its lower price
compared to branded alendronate in Germany. The perspective
for this analysis was the German Social Insurance (GSI) system
that encompasses several health-care sectors: treatment and acute
hospitalization covered by statutory health insurance (SHI, Kran-
kenversicherung), rehabilitation covered by pension insurance
and long-term care (LTC) covered by long-term care insurance
(Pﬂegeversicherung).
Model Overview
The model used in the current study is consistent with an
osteoporosis reference model proposed by Zethraeus et al. [32]
and has been used in prior analyses of risedronate in Germany
and other countries globally [33–36]. The validity and technical
accuracy of the model has been well-documented and these
details are provided elsewhere [31–37].
The model is a state-transition cohort model that uses a
1-year cycle length and a fracture incidence-based approach to
simulate the occurrence of fractures and the impact of therapy. At
the start of the model, a cohort of patients begins in the “well”
state, and each year remains in the “well” state or moves to
alternative health states according to state- and age-dependent
transition probabilities (see Fig. 1). Patients who experience a hip
fracture transition to the “1st hip fracture” state and remain in
this state for the year. At the end of the year, patients transition
to either the “post–1st hip fracture” state or the “dead” state,
depending on the transition probabilities. Once in the “post–1st
hip fracture” state, patients may remain in that state, experience
a 2nd hip fracture, or die due to causes other than hip fracture.
Patients surviving a second hip fracture enter the “post–2nd hip
fracture” state where they either remain or die due to other
(non-fracture related) causes.
Each health state is associated with an economic cost and a
health utility weight, which are used to estimate the hip fracture-
related costs and quality-adjusted life years (QALYs), respec-
tively. The post–hip fracture states capture the long-term cost and
quality-of-life impacts of chronic morbidity associated with hip
fractures. Annual cost and QALY data for each year in the model
were summed to estimate the total outcomes for the cohort.
Patient Population
The population for this analysis included women 65 years of age
or older with osteoporosis (with or without a previous vertebral
fracture) and a BMD T-score of -2.5 and reﬂected the broad
range of patients for which bisphosphonates are recommended as
a treatment option in Germany [38]. A population analysis was
completed for Germany using German-speciﬁc data for the age-
speciﬁc prevalence of osteoporosis and age-speciﬁc prevalence of
existing vertebral fracture [1,39].
The analysis considered eight cohorts with unique risk pro-
ﬁles, deﬁned according to: 1) age (65–69, 70–74, 75–79, and
80+); and 2) presence or absence of a prevalent vertebral frac-
ture, as both age and vertebral fracture are strong predictors of
future fracture [40]. The costs, fractures, and QALYs calculated
for each of the eight cohorts were weighted based on the esti-
mated proportion of the population that comprised each cohort
in Germany. These proportions were derived using general popu-
lation data from the Federal Statistical Ofﬁce (Statistisches
Bundesamt) [41] and combined with the estimated prevalence of
osteoporosis in each age group for Germany [1] (see Table 1).
This was then utilized in conjunction with data on the age-
speciﬁc prevalence of existing vertebral fractures in the female
population in Germany [39]. Because data on the prevalence of
vertebral fractures in women 80+ years of age were not available,
the proportion was assumed to be equivalent to that reported for
women 75 to 79 years of age.
Model Inputs
Fracture Incidence
To further adapt the model to capture Germany-speciﬁc fracture
risk, age-speciﬁc incidence of hip fracture for 2005 to 2006 from
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Figure 1 Simpliﬁed structure of the model health states and transitions.
Table 1 Distribution of women among the eight cohorts deﬁned by age
and previous vertebral fracture for the model based on German-speciﬁc
prevalence data*
Age (years)
Proportion of osteoporotic
population over 65 years (%)
Previous vertebral
fracture (%)
65–69 27 13.5
70–74 19 16.3
75–79 22 24.8
80+ 32 24.8
*Age-speciﬁc breakdown of osteoporosis proportions based on data provided from a
German sickness fund covering 1.5 million beneﬁciaries and billing data for outpatient visits
that estimated osteoporosis prevalence in Germany [1]. Prevalence of vertebral fracture was
based on a multicenter, cross-sectional population-based survey of 1916 women in Germany
[39].
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Federal Statistical Ofﬁce was utilized [41] (Table 2). Although
these data were speciﬁc to women, they were not speciﬁc to
women with postmenopausal osteoporosis, the target population
for this analysis. These general population fracture estimates
were, therefore, adjusted to reﬂect the increased risk of fracture
in women with low BMD using a methodology reported by Black
et al. 2006 [42]. The relative risk values that were used in the
base-case analysis are presented in Table 3 and compared to an
independent study by Kanis et al. [19] that reports similar values.
Utilizing these age-speciﬁc relative risk values, the published
general population fracture incidence rates reported in Germany
were adjusted to obtain the estimated fracture incidence rates for
the target population of the analysis (i.e., German postmeno-
pausal women with osteoporosis, with or without previous
vertebral fracture).
Mortality
The age-speciﬁc probabilities of death in the general population
were derived from Federal Statistical Ofﬁce [41]. To estimate
hip fracture mortality, the relative risk of mortality in the year
after hip fracture was obtained from Kanis et al. [43] and mul-
tiplied by the German-speciﬁc general population mortality to
obtain the probability of death associated with hip fracture.
There have been a number of publications, however, which
have reported that not all deaths associated with hip fracture
are attributable to the fracture and thus preventable by averting
the fracture [43–45]. In the recently published osteoporosis
“reference model,” only 30% of deaths occurring in the year
after the hip fracture were assumed to be causally related to the
fracture [32]. Therefore, in the analysis, excess mortality in the
year after the hip fracture was reduced by 70% to avoid over-
estimating the impact of fracture on associated mortality. In the
base-case, it was assumed that there was only an excess mor-
tality associated with hip fracture for the ﬁrst year, as the
excess mortality is greatest immediately after the fracture
[44,45] (Table 2).
Treatment Effectiveness
The REAL study, which assessed the incidence of hip and non-
vertebral fractures more than 12 months after the initiation of
risedronate or alendronate therapy, provided the effectiveness
Table 2 Summary of key model input data
Parameter Value Source
All-cause annual mortality (per 1000 patients)
65–69 years 9.52 Federal Statistical Ofﬁce (Statistisches Bundesamt) [Germany]
[41]70–74 years 16.94
75–79 years 31.62
80–84 years 62.10
Relative risk of mortality in the year following hip fracture Relative risk multiplied by general population mortality to
obtain mortality associated with hip fracture in German
population.These values then adjusted downward 70%,
based on Zethraeus et al. [32], to avoid overestimating the
beneﬁcial effects of treatment on mortality (Kanis et al.
[43])
65–69 years 4.41
70–74 years 3.58
75–79 years 2.74
80–84 years 2.09
Hip fracture incidence in the German female population
(per 1000)
65–69 years 1.885 Federal Statistical Ofﬁce (Statistisches Bundesamt) [Germany]
[41]70–74 years 4.086
75–79 years 8.539
80–84 years 16.849
Relative risk of hip fracture in women aged 65 and
BMD -2.5
No previous
fracture
Previous
fracture
Based on methods from Black et al. [42]
65–69 years 4.18 6.41
70–74 years 2.73 4.03
75–79 years 2.73 3.91
80–84 years 1.83 2.53
Health utility for general population Burström et al. (Sweden) [47]
60–69 years 0.78
70–79 years 0.78
80–89 years 0.74
Multipliers for health utility decrements
Year of hip fracture 0.792 Kanis et al. [48], Zethraeus et al. [32]
2nd Year
3 years +
0.813
0.90
Drug costs (€)
Risedronate 507.35 Lauer-Taxe online (Germany) [49]; Co-payment of 43.33 €
subtracted as this is reimbursed.
Generic alendronate 273.39 Lauer-Taxe online (Germany) [49]
Hip fracture costs (€)
Year of hip fracture 24,580* Brecht et al. (Germany) [33]
Each subsequent year following hip fracture 12,167* Brecht et al. (Germany) [33]
*The costs, captured in 1995 and 1996, were updated to 2008 Euros using the medical care component of the Consumer Price Index for Germany (Federal Statistical Ofﬁce (Statistisches
Bundesamt) [Germany] [41]).
BMD, bone mineral density.
Table 3 Relative risk of fracture compared to the general population
risk, as reported by Kanis et al. and as utilized in the current analysis
Age (years) Kanis et al. [19] Current analysis
65–69 3.51 4.18
70–74 2.95 2.73
75–79 2.43 2.73
80–84 2.09 1.83
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data for the model [26]. The study included 33,830 women
65 years of age or older from commercially available datasets of
health-care utilization (from the 1 health plan within Ingenix
Lab/RX Database and more than 100 health plans of employers
within the Marketscan® Commercial Claims and Encounter
database) who initiated once-a-week risedronate or alendronate
between July 2002 and September 2004. The study found that
patients treated with risedronate had an 18% (95% CI: 0.02–
0.32) lower incidence of nonvertebral fractures and a 43% (95%
CI: 0.13–0.63) lower incidence of hip fractures at 12 months,
compared to alendronate.
In addition to a direct comparison of risedronate and alendr-
onate, both the risedronate and alendronate treatment arms were
compared with 3060 “no therapy” patients in the REAL study
[46]. “No therapy” patients were deﬁned as those who received
only one prescription for either risedronate or alendronate and
no additional bisphosphonate use, and their reported hip fracture
incidence was 0.8% [46]. This incidence was comparable to the
incidence rates calculated at 12 months for the placebo group of
the risedronate RCT (i.e., 1.1%) [8], as well as the alendronate
RCT (i.e., 0.7%) [4]. The REAL study found a relative risk of
0.493 (P = 0.01) for hip fracture for risedronate compared to no
therapy and 0.882 (P = 0.59) for alendronate compared to no
therapy, over a 12-month period [46]. In the model, the adjusted
age-speciﬁc fracture rates in the “no therapy” group were mul-
tiplied by the fracture reduction measures to estimate fracture
rates in the treated cohorts.
One year of treatment with risedronate and alendronate was
assumed, as this was the observation period of the REAL study
from which the treatment effectiveness data were derived. It was
further assumed that there was no discontinuation over the
1-year treatment period for comparison to other osteoporosis
models that frequently use this assumption, although a published
discontinuation pattern speciﬁc to Germany was assumed in a
sensitivity analysis. For simplicity, the model assumed no residual
effect; upon discontinuation of treatment at 1 year, the fracture
risk returned immediately to that of osteoporotic women with no
treatment. It was also assumed that generic alendronate was
equivalent in efﬁcacy to branded alendronate.
Health Utility and Costs
Health utility values for the general population were not avail-
able for Germany. Thus, for patients in the “well” state (e.g.,
patients that have not fractured) the calculation of QALYs was
based on age-speciﬁc utility values published for Sweden [47]
(see Table 2). For patients in the “post hip fracture” state, utility
values were derived by applying a multiplier of 0.792 [48] to
the age-speciﬁc general population utility values. In the follow-
ing year, a utility multiplier of 0.813 was applied, and in all
subsequent years 3+, the utility multiplier was assumed to
increase to 0.90 for patients in the “post hip fracture” state
[32,48].
Annual German-speciﬁc drug costs for risedronate
(€507.35) and generic alendronate (€273.39) were obtained
from Lauer-Taxe online [49] (Table 2). Annual drug costs for
risedronate and alendronate were calculated using the following
formulas (1.39 ¥ 365 = 507.35, 0.7490 ¥ 365 = 273.39). A
patient co-payment value of €43.33 was subtracted from the
risedronate cost given that the GSI would reimburse this value.
There is no copayment for generic alendronate. The costs of
hip fracture in the ﬁrst year after the fracture and in each year
subsequent to the fracture were taken from a published
German study [33]. The costs, captured in 1995 to 1996, were
updated to 2008 Euros using the medical care component of
the Consumer Price Index (CPI) for Germany [41] (see
Table 2).
Analysis
We conducted analyses to estimate the clinical and economic
impact of treatment with risedronate compared to generic alen-
dronate in the German population of postmenopausal women
65 years of age and older with osteoporosis. Patients were
treated for 1 year and followed in the model for an additional
4 years to capture the ongoing impact of the difference in frac-
tures during the ﬁrst year on costs, life years and QALYs in
subsequent years. Although guidelines for economic evaluations
often recommend a lifetime horizon where the disease or therapy
has a chronic impact, a shorter time horizon was considered
based on the 1-year duration of the REAL study. A cost-
effectiveness analysis was performed using the incremental cost
per hip fracture avoided and the cost per QALY gained. Costs
and outcomes were discounted at a rate of 3%.
The analysis focused on hip fracture alone as hip fractures
have the greatest clinical (morbidity and mortality) and economic
consequences (costs) of all osteoporotic fractures. Vertebral frac-
tures were not considered as the effectiveness data were not
available from REAL; however, it should be noted that clinical
data do not suggest differences in efﬁcacy between alendronate
and risedronate in vertebral fracture risk [4,9]. Although the
REAL study did provide effectiveness data for nonvertebral frac-
tures that showed a beneﬁt of risedronate over alendronate,
comprehensive data for nonvertebral fracture costs and incidence
rates are not available for Germany and thus not included in the
analysis.
Probabilistic Sensitivity Analysis
The analysis incorporated a probabilistic sensitivity analysis
(PSA) using the 95% CI for the relative risk of fracture for
risedronate (range 0.28 to 0.86) and alendronate (range 0.56 to
1.40). A triangular distribution was used to characterize the
relative risk of fracture associated with risedronate and alend-
ronate treatment to allow for relative risk reductions in a
negative range. A lognormal distribution could not be used for
alendronate, as the relative risk reduction in the model would
cross 0. Fracture costs were varied as well, using a normal
distribution for year of hip fracture (range €13,745 to €35,414)
and each subsequent year (range €3455 to €20,878). Lower
bound estimates were based on the lowest observed cost data
reported in Germany. Upper bound estimates were derived by
applying the same percentage difference between the lower
bound and base-case fracture costs. Crystal Ball Pro 7.3 (2007)
software (Oracle Corporation, Redwood Shores, CA) was used
to simulate a total of 1000 model runs. For each model run, a
random number was selected for each distribution, assuming
independence of distributions, and a relative risk value from the
distributions was selected for each therapy. The model was then
run using the selected relative risk value and a cost-effectiveness
ratio calculated. The cost-effectiveness results for the 1000 model
runs were combined to determine: 1) the proportion of runs in
which risedronate was dominant (lower costs and better out-
comes); 2) the proportion of runs in which generic alendronate
was dominant; 3) the proportion of runs in which risedronate
was more effective and more costly; and 4) the proportion of runs
in which risedronate was less effective but less costly. For option
3, the cost-effectiveness ratios of risedronate versus alendronate
were calculated. Results were then summarized as the proportion
of runs among 1 to 3 in which risedronate was dominant or the
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cost per fracture averted/cost per QALY gained fell below accept-
able thresholds of €5000, €10,000, €15,000, €20,000, €25,000,
and €30,000.
Other Sensitivity Analyses
One-way deterministic sensitivity analyses were also performed
to determine the impact on the base-case results of uncertainty in
key model inputs:
1. Two years of treatment instead of 1 year was assumed, with
effectiveness of risedronate and alendronate equal in year 2
(e.g., 0.493 relative risk vs. no therapy for both risedronate
and alendronate).
2. Regarding hip fracture mortality, two unique methodologi-
cal assumptions were made to further assess the variability
reported in the literature:
• assuming that 100% of associated hip fracture mor-
tality is caused by the hip fracture; and
• hip fracture mortality risk extending beyond the ﬁrst
year, up to 5 years based on a recent data source [50].
3. For treatment discontinuation, German-speciﬁc data were
used for discontinuation rate of therapy (i.e., 54% by
12 months, where the majority (33%) discontinued by the
fourth month) [51]. A hypothetical analysis incorporating
half of this discontinuation rate (i.e., 27%) was also
completed.
4. Hip fracture-related costs were lowered utilizing German
speciﬁc data [1]; however, it should be noted that detailed
costs speciﬁc to hip fractures were not comprehensive and
thus the hip fracture-related costs from these data may be
underestimated. These German costs were €13,745 and
€3455 for year of hip fracture and each subsequent year
respectively.
5. Hip fracture incidence rates were lowered using an alternate
German data source [52].
6. The price of generic alendronate is predicted to decrease in
Germany, thus we reduced the price by 10% and 30%.
7. Utility values were assumed to be different for women with
and without a vertebral fracture. Speciﬁcally, for women
with a previous vertebral fracture, the starting general
population utility values were adjusted downward using a
multiplier of 0.913 [48].
8. Analyses were conducted from the SHI perspective that
includes ﬁrst year treatment and hospitalization costs but
excludes LTC costs in ﬁrst and subsequent years.
9. A discount rate of 5% was used on costs and outcomes.
Finally, given the high likelihood of a future alendronate price
reduction, as well as the uncertainty associated with a limited
1-year treatment period, we conducted a two-way sensitivity
analysis incorporating a 2-year treatment period and maximum
predicted alendronate price reduction of 30%.
Results
Over the 1-year treatment period and 4-year follow-up period,
treatment with risedronate resulted in fewer fractures and addi-
tional QALYs relative to treatment with alendronate (Table 4).
Eight additional hip fractures were averted and 4.1 QALYs were
gained (discounted values) per 1000 women treated with risedr-
onate versus alendronate. Under the base-case scenario, treat-
ment with risedronate was also cost-saving: the net present value
of the associated cost savings from the perspective of the GSI was
€278 per woman treated with risedronate versus alendronate.
Risedronate, therefore, provided additional fracture protection
at a lower cost than alendronate.
Sensitivity Analysis
In more than 79% of the PSA simulations, risedronate remained
the dominant therapy, as it was less costly and more effective
compared to generic alendronate. In more than 80% of the
simulations, the cost per fracture averted and the cost per QALY
gained for risedronate compared to generic alendronate was
below €30,000 (Fig. 2).
The base-case analysis assumed the perspective of the GSI.
When the perspective of the SHI only was adopted, risedronate
remained the most effective therapy in terms of fractures averted
and QALYs gained; however, it was no longer the less costly
therapy. The analysis resulted in a cost per fracture averted of
€11,016 and a cost per QALY gained of €21,486 (Table 4).
Similarly, the direction of the result changed, but to a lesser
extent, when varying the data source for hip fracture costs
(Table 5).
For all remaining one-way sensitivity analyses (Table 5),
risedronate remained the dominant therapy compared to generic
alendronate. In terms of the cost savings attributable to risedr-
Table 4 Results (per 1000 patients) for two German perspectives (GSI,
SHI) for women 65 years of age with BMD -2.5 (with or without
previous vertebral fracture) treated for 1 year, with a time horizon of
5 years
Risedronate
Generic
alendronate
Total costs (GSI perspective) 3,648,517 € 3,926,804 €
Total costs (SHI perspective) 1,432,576 € 1,344,313 €
Total hip fractures 79 87
Incremental cost/fracture averted
(GSI perspective)
Win/Win —
Incremental cost/fracture averted
(SHI perspective)
11,016 € —
Total QALYs 3,302 3,298
Incremental cost/QALY gained
(GSI perspective)
Win/Win —
Incremental cost/QALY gained
(SHI perspective)
21,486 € —
BMD, bone mineral density; GSI, German Social Insurance; QALY; quality-adjusted life years;
SHI, Statutory Health Insurance.
Figure 2 Probabilistic sensitivity analysis based on upper and lower bound
estimates for efﬁcacy and fracture cost for risedronate and alendronate.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year;
= cost per hip fracture averted; = cost per QALY gained.
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onate, the base-case results were most sensitive to alternative
assumptions regarding treatment duration, therapy discontinua-
tion, and cost of generic alendronate.
When the treatment duration was increased to 2 years and
the effectiveness of risedronate compared to generic alendronate
was equal in year two, the cost savings attributable to risedronate
decreased from the base case of €278 to €106 per patient. When
utilizing recent German data on discontinuation rates of bispho-
sphonates (i.e., 54% by 12 months), results still remained cost
saving but the associated cost savings with risedronate decreased
by approximately 40% to €162 per patient. Due to uncertainty in
future drug prices in Germany, a sensitivity analysis was con-
ducted that considered the impact of lowering the cost of alen-
dronate. When the cost associated with generic alendronate was
decreased by 10%, the cost savings associated with risedronate
decreased by approximately 10% to €251 per patient. When the
cost of alendronate was decreased by 30%, cost savings
decreased by approximately 30% to €197 per patient.
Alternative assumptions regarding discount rate, post–hip
fracture mortality and utility resulted in only minor increases or
decreases in the cost savings associated with risedronate. In none
of these analyses did the estimated cost savings ﬂuctuate by more
than 10%. One interesting ﬁnding was when assuming higher hip
fracture-related mortality (i.e., either more deaths caused by hip
fracture or hip fracture mortality persisting beyond 1 year), there
were more QALYs gained with risedronate therapy.
Lastly, Table 5 additionally describes the results of a two-way
sensitivity analysis that was conducted varying the alendronate
price reduction to 30% and assuming a 2-year treatment dura-
tion. Results show that risedronate is no longer cost savings, but
remains cost-effective when compared to alendronate.
Discussion
The recently published results of the REAL study, which quan-
tiﬁed the comparative effectiveness of risedronate and alendr-
onate in actual clinical practice, provide an opportunity to
explore the cost-effectiveness of risedronate versus generic alen-
dronate using real-world data. We applied these data in an analy-
sis of women typically treated in Germany for osteoporosis, by
simulating multiple cohorts of women 65 years of age or older
with a BMD -2.5, with or without a previous vertebral frac-
ture. The base-case analysis considered the perspective of the
GSI, and results showed that therapy with risedronate versus
alendronate resulted in fewer hip fractures and more QALYs, at
a reduced cost. The results reﬂect the larger 12-month fracture
reduction for risedronate compared to alendronate observed in
the REAL study. Further, when incorporating the uncertainty in
the effectiveness of risedronate and alendronate, the PSA analysis
showed that risedronate was the dominant therapy in close to
80% of simulations.
The strength of the present analysis is in its use of compara-
tive effectiveness data from the REAL study. Previous economic
evaluations involving alendronate and risedronate have mainly
relied on combining efﬁcacy data from noncomparative clinical
trials that were heterogeneous in terms of patient inclusion/
exclusion criteria, baseline demographics, clinical assessment of
fracture outcomes and statistical approach. Only one published
economic evaluation utilized the REAL data for comparison of
alendronate and risedronate in a Canadian analysis [28]. Results
were comparable to our German study in that more fractures
were averted and more QALYs were gained with risedronate
relative to alendronate therapy. Nevertheless, although the Cana-
dian analysis showed a favorable incremental cost-effectiveness
ratio (i.e., $3877 per QALY gained) for risedronate compared to
generic alendronate, the current German study results are unique
in that cost savings were achieved in the base-case and a majority
of the sensitivity analyses. This difference shows that factors
affecting the results extend beyond the effectiveness data, and are
likely attributable to region-speciﬁc parameters, such as fracture
incidence and treatment costs.
As described, the use of effectiveness data in an economic
evaluation is preferable to efﬁcacy data, and ideally these data
would be available from a German population, thus the lack of
German-speciﬁc effectiveness data is a limitation of the study.
Nevertheless, given published US census and prevalence data
[53,54], it is estimated that the majority of the osteoporotic
population 65+ in the United States is Caucasian and thus are
racially similar to Germany. There are also a few important
factors noted in the REAL study that would increase conﬁdence
in generalizability: 1) the population within the REAL study was
very large (i.e., >35,000 patients) and drawn from multiple
health plans in many US states; 2) the population consists of
subjects with a wide mixture of health characteristics; 3) obser-
vations of fracture rates in the database are consistent with
clinical trial data; and 4) the length of observation of therapy
Table 5 Sensitivity analysis results per 1000 osteoporotic patients in Germany. Results are expressed for risedronate relative to alendronate
Parameter
Total cost
savings
Total hip
fractures
averted
Total QALYs
gained
Cost per
hip fracture
averted
Cost per
QALY gained
Base-case 278,287 € 8.01 4.11 Win-Win Win-Win
Treatment duration = 2 years 105,677 € 8.02 4.14 Win-Win Win-Win
Mortality post–hip fracture
1. 100% deaths caused by fracture 251,331 € 7.96 5.54 Win-Win Win-Win
2. Excess mortality persists up to 5 years 271,458 € 8.00 4.48 Win-Win Win-Win
Discontinuation of Therapy:
1. 27% by 12 months (Assumption) 217,740 € 6.49 3.33 Win-Win Win-Win
2. 54% by 12 months (German data) 161,737 € 5.09 2.62 Win-Win Win-Win
Fracture incidence: Lower rates (German data) 131,400 € 5.41 2.81 Win-Win Win-Win
Utility: differs by vertebral fracture presence 278,307 € 8.01 4.00 Win-Win Win-Win
Fracture costs: lower values (German data) (1,179 €) 8.01 4.11 147 € 287 €
SHI perspective (excludes LTC costs) (88,263 €) 8.01 4.11 11,016 € 21,486 €
Potential alendronate price reductions:
1. Decrease by 10% 251,365 € 8.01 4.11 Win-Win Win-Win
2. Decrease by 30% 197,519 € 8.01 4.11 Win-Win Win-Win
Discounting: 5% 264,602 € 7.98 3.96 Win-Win Win-Win
Treatment = 2 years, 30% price decrease (50,936 €) 8.02 4.14 6,349 € 12,291 €
LTC, long-term care; QALY; quality-adjusted life years.
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adherence was consistent to previously reported average dura-
tion of adherence to bisphosphonates. The population character-
istics of the REAL study (i.e., women more than 65 years, new
users of bisphosphonates, exclusion of secondary causes of
osteoporosis) suggest that the population is comparable to our
modeled study; however, with one important caveat: the REAL
study most likely included a proportion of women with higher
BMD (i.e., osteopenia) and therefore may reﬂect a lower risk
population. There is some evidence that suggests differences in
treatment effect with different osteoporosis risk groups [25];
however, the implications of this are uncertain at this time given
lack of complete data on fracture history and bone density levels
in the REAL study. Thus, when extending these results to
Germany, we must note that our study modeled a speciﬁc popu-
lation at risk of postmenopausal women aged 65 years or older
with osteoporosis (with or without vertebral fractures) and the
results of our analysis would be most applicable to this high-risk
population in Germany.
It is important to point out the methodological limitations of
the REAL study that are common to observational studies. In
particular, there is the possibility that systematic errors (e.g.,
selection bias, measurement misclassiﬁcation) contribute to
observed differences. Although selection bias may arise from
differences in fracture risk between the two cohorts of patients at
the start of therapy, the near unity in fracture incidence between
the two cohorts during the ﬁrst 3 months of therapy suggest that
both cohorts had similar risk for fracture at the initiation of
therapy. Misclassiﬁcation of fracture events and therapy use
within health-care utilization data are inevitable; however, given
previous research on the accuracy of fracture claims, it is likely
that there may be less misclassiﬁcation with hip fracture out-
comes. These study limitations were addressed in detail in the
original publication and explored extensively through sensitivity
analyses [26].
The analysis is subject to the limitations imposed by the use of
any decision modeling technique. We employed conservative
assumptions in the base-case analysis, such that the effectiveness
difference between risedronate and alendronate would be
based on the effectiveness data in the ﬁrst year. For example: 1)
we excluded residual effect of therapy after stopping
treatment—efﬁcacy is often assumed to decline linearly over a
period equal to the treatment period; and 2) time horizon was
limited to 5 years even though beneﬁts of fracture avoidance
would continue after that point. In addition, uncertainty in
underlying model assumptions and key model parameters were
addressed, where feasible, through probabilistic sensitivity and
one-/two-way deterministic sensitivity analyses. The magnitude
of the cost savings observed in the base-case was sensitive to
alternative assumptions regarding treatment duration, therapy
discontinuation and cost of generic alendronate. Results were
however most sensitive to assumptions that reﬂect differences in
fracture treatment costs (i.e., lower fracture treatment costs, SHI
perspective that excludes LTC costs), changing the results from
the direction of cost-savings to incremental cost-effectiveness.
Based on these sensitivity analyses, results were still cost-effective
by international standards with the highest ratio reported to be
€21,486 per QALY [55].
The base-case analysis was limited to 12 months of treatment
and short-term follow-up to reﬂect the REAL study. As long-term
follow-up data become available, the impact of long-term treat-
ment with risedronate and alendronate may be investigated.
Longer-term data in the second year of treatment may show a
smaller difference in efﬁcacy between the two products. Notably,
even under the assumption that the products have equal efﬁcacy
in year two, risedronate remains cost saving (€106), implying
that the value of early fracture protection is €106 if patients are
treated for 2 years.
The results of the analysis are consistent with published cost-
effectiveness analyses of risedronate in Germany. Brecht et al.
(2003) [33] found risedronate to be cost-effective in an analysis
versus the current standard treatment in Germany for women at
high risk of osteoporotic fracture because of low BMD
(T-score  -2.5) and a history of previous vertebral fracture.
From the perspective of the GSI and over a 3-year treatment
period and a 10-year time horizon, risedronate dominated the
current average treatment in Germany with net cost savings of
€340 per treated woman. From the perspective of the SHI, treat-
ment with risedronate resulted in a cost per hip fracture averted
of €33,856 and a cost per QALY gained of €35,690. In a similar
modeling study [56], the authors conducted a comparative cost-
effectiveness analysis of risedronate, alendronate, raloxifene, and
“no therapy” for German patients at high risk of osteoporotic
fracture because of low BMD (T-score  -2.5) and a history of at
least one previous vertebral fracture. The base-case analysis was
conducted on a cohort of 1000 women 70 years of age, more
than 3 years of treatment, and a 10-year time horizon. Treatment
with risedronate was cost saving compared to alendronate and
raloxifene. In the Brecht study [56], brand alendronate prices
were used, unlike the current analysis that used generic alend-
ronate prices. Thus, it is important to note that when incorpo-
rating real-world effectiveness data and the lower generic
alendronate prices, our results still show the favorable cost-
effectiveness of risedronate relative to alendronate. The current
analysis is limited in that it does not incorporate raloxifene
therapy because the model does not cover the extraskeletal effects
of such therapy. Nevertheless, bisphosphonates are increasingly
being used as ﬁrst-line therapies in this population. Future analy-
ses will however need to consider comparisons to once-yearly
intravenous bisphosphonates, once more data become available.
Conclusion
When the REAL study effectiveness data are considered in a
cost-effectiveness framework, cost savings are indicated, provid-
ing strong support for the use of risedronate compared to generic
alendronate for the treatment of osteoporotic German women,
65 years of age or older at risk of fracture.
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